These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12962763)

  • 1. Tacrolimus in induction immunosuppressive treatment in renal transplantation: comparison with cyclosporine.
    Solà R; Díaz JM; Guirado L; Sainz Z; Gich I; Picazo M; García R; Abreu E; Ortiz F; Alcaraz A
    Transplant Proc; 2003 Aug; 35(5):1699-700. PubMed ID: 12962763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
    Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
    Bunnapradist S; Daswani A; Takemoto SK
    Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group.
    Forsythe J
    Transplant Proc; 1999 Nov; 31(7A):69S-71S. PubMed ID: 10576049
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients.
    Kim SJ; Lee KW; Lee DS; Lee HH; Lee SK; Kim B; Huh WS; Oh HY; Joh JW
    Transplant Proc; 2004 Sep; 36(7):2098-100. PubMed ID: 15518759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group
    Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
    Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
    Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
    Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation.
    Cantarovich D; Giral-Classe M; Hourmant M; Dantal J; Blancho G; Lerat L; Moreau A; Soulillou JP
    Nephrol Dial Transplant; 2000 Oct; 15(10):1673-6. PubMed ID: 11007839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
    Sánchez-Fructuoso AI; Prats D; Marques M; Ridao N; Conesa J; García Mena M; Torrente J; Barrientos A
    Transplant Proc; 2003 Aug; 35(5):1689-90. PubMed ID: 12962759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
    Miller J; Mendez R; Pirsch JD; Jensik SC
    Transplantation; 2000 Mar; 69(5):875-80. PubMed ID: 10755543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients.
    Birkeland SA
    Transplantation; 2001 Apr; 71(8):1089-90. PubMed ID: 11374407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years.
    Höcker B; John U; Plank C; Wühl E; Weber LT; Misselwitz J; Rascher W; Mehls O; Tönshoff B
    Transplantation; 2004 Jul; 78(2):228-34. PubMed ID: 15280683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection.
    Boratyńska M; Banasik M; Patrzałek D; Klinger M
    Ann Transplant; 2006; 11(2):51-6. PubMed ID: 17494290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.